Journal of Chest Surgery

  • 제40권6호
  • /
  • Pages.399-406
  • /
  • 2007
  • /
  • 2765-1606(pISSN)
  • /
  • 2765-1614(eISSN)
대한심장혈관흉부외과학회 (The Korean Society for Thoracic and Cardiovascular Surgery)
권호 표지

승모판막수술 시 히스티딘를 함유한 결정성 심정지액(Histidine-tryptophan-ketoglutarate Solution)과 저온 혈성 심정지액이 심근기능 보존에 미치는 영향 비교

A Comparison of the Effects of Histidine-tryptophan-ketoglutarate Solution versus Cold Blood Cardioplegic Solution on Myocardial Protection in Mitral Valve Surgery

  • 최용선 (연세대학교 의과대학 마취통증의학교실) ;
  • 방서욱 (연세대학교 의과대학 마취통증의학교실) ;
  • 장병철 (연세대학교 의과대학 흉부외과학교실, 심혈관연구소) ;
  • 이삭 (연세대학교 의과대학 흉부외과학교실, 심혈관연구소) ;
  • 박철희 (연세대학교 의과대학 마취통증의학교실) ;
  • 곽영란 (연세대학교 의과대학 흉부외과학교실, 심혈관연구소)
  • Choi, Yong-Seon (Department of Anesthesiology and Pain Medicine, Yonsei University College of Medicine) ;
  • Bang, Sou-Ouk (Department of Anesthesiology and Pain Medicine, Yonsei University College of Medicine) ;
  • Chang, Byung-Chul (Department of Thoracic and Cardiovascular Surgery, Yonsei Cardiovascular Research Institute, Yonsei University College of Medicine) ;
  • Lee, Sak (Department of Thoracic and Cardiovascular Surgery, Yonsei Cardiovascular Research Institute, Yonsei University College of Medicine) ;
  • Park, Chol-Hee (Department of Anesthesiology and Pain Medicine, Yonsei University College of Medicine) ;
  • Kwak, Young-Lan (Department of Thoracic and Cardiovascular Surgery, Yonsei Cardiovascular Research Institute, Yonsei University College of Medicine)
  • 발행 : 2007.06.05
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

배경: 개심술 시 불충분한 심근 보호로 인한 허혈과 재관류 손상은 술 후 심실 기능과 예후에 영향을 미친다. 본 저자들은 승모판막 수술에서 HTK 용액과 냉혈 혈성 심정지액이 심근 보호와 임상 결과에 미치는 영향을 전향적으로 비교 분석하였다. 대상 뜻 방법: 승모판막폐쇄부전으로 승모판막수술을 받는 70명의 환자 중 8명의 환자를 제외한 31명에서 HTK 용액을(HTK군), 31명에서 냉혈 혈성 심정지액을(CBC군) 사용하였다. 수술 중과 후에 환자의 혈역학, 심혈관계 약물과 심장박동조율기의 사용, 임상경과 및 합병증을 관찰하였다. 모든 환자에서 최소 6개월 이상 사망률과 이환율을 추적 관찰하였다. 결과: 혈역학적 변수는 평균폐동맥압, 중심정맥압과 폐모세혈관쐐기압이 체외순환으로부터 이탈 후 시기에 HTK군에서 유의하게 낮았던 점을 제외하고는 모든 시기에서 군 간 차이가 없었다. 심근수축제와 심장박동조율기의 사용은 모든 시기에서 군 간 차이가 없었다. 수술 후 1일과 2일째 CK-MB 수치는 HTK군에서 $77{\pm}54,\;41{\pm}23$ (ng/mL)로 CBC군의 $70{\pm}69,\;44{\pm}34$ (ng/mL)와 유의한 차이가 없었다. 6개월 이상의 추적관찰 중 임상경과는 비슷하였다. 결론: 이상의 결과에서 HTK 용액은 냉혈 혈성 심정지액과 비슷한 심근 보호효과를 가짐을 확인할 수 있었다.

Background: Ischemia-reperfusion injury related to unsuccessful myocardial protection affects postoperative ventricular function and mortality during open-heart surgery. We prospectively compared the effects of administration of histidine-tryptophan-ketoglutarate (HTK) solution and cold blood cardioplegia (CBC) on myocardial protection and clinical outcome in patients undergoing mitral valve surgery. Material and Method: Seventy patients with mitral regurgitation (MR) undergoing mitral valve surgery were randomly divided into the HTK group (n=31) and the CBC group (n=31 ): eight patients were excluded. Perioperative hemodynamics, cardiac medications, pacing, postoperative outcomes and complications were recorded during the hospital stay. All patients received follow-up for at least 6 months postoperatively for morbidity and mortality. Resuか: There were no significant differences in the hemodynamics between the groups during the study period, except for the mean pulmonary artery pressure (MPAP), PCWP and CVP that were lower in the HTK group at 15 min after weaning of CBP. There were no differences for inotropic support and pacing during the 12 hrs postoperatively between the groups. CK-MB values on day 1 and day 2 were $77{\pm}54$ and $41{\pm}23$ for the HTK group and $70{\pm}69$ and $44{\pm}34$ for the CBC group, respectively (p=NS). Postoperative clinical outcomes were similar in both groups for at least 6 months during the follow-up period. Conclusion: These results suggest that the use of HTK solution is as safe as cold blood cardioplegia in terms of myocardial protection.

키워드

참고문헌

  1. Bretschneider HJ, Hubner G, Knoll D, Lohr B, Nordbeck H, Spieckermann PG. Myocardial resistance and tolerance to ischemia: physiological and biochemical basis. Cardiovasc Surg 1975;16:241-60
  2. Bretschneider HJ. Myocardial protection. Thorac Cardiovasc Surg 1980;28:295-302 https://doi.org/10.1055/s-2007-1022099
  3. Lee DH, Park NH, Keum DY, Choi SY, Lee KS, Yoo YS. Comparison of myocardial protective effect between the cold blood cardioplegia and histidine-triptophan- ketoglutalate solution. Korean J Thorac Cardiovasc Surg 2004;37:735-41
  4. Lee C, Kim YJ. A prospective clinical trial of histidinetriptophan- ketoglutalate solution in congenital heart surgery. Korean J Thorac Cardiovasc Surg 2003;36:483-8
  5. Sakata J, Morishita K, Ito T, Koshino T, Kazui T, Abe T. Comparison of clinical outcome between histidine-triptophanketoglutalate solution and cold blood cardioplegic solution in mitral valve replacement. J Card Surg 1998;13:43-7 https://doi.org/10.1111/j.1540-8191.1998.tb01053.x
  6. Carpentier A, Chauvaud S, Fabiani JN, et al. Reconstructive surgery of mitral valve incompetence: ten-year appraisal. Thorac Cariovasc Surg 1980;79:338-48
  7. Del Nido PJ, Wilson GJ, Mickle DAG, et al. The role of carioplegic solution buffering in myocardioal protection. J Thorac Cardiovasc Surg 1985;89:689-99
  8. Kubler W, Spieckermann PG. Regulation of glycolsis in the ischemic and anixic myocardium. J Mol Cell Cardiol 1970; 1:351-77 https://doi.org/10.1016/0022-2828(70)90034-9
  9. Bretschneider HJ, Hubner G, Knoll B, Lohr B, Nordbeck H, Spieckermann PG. Myocardial resistance and tolerance to ischemia: physiological and biochemical basis. J Thorac Cardiovasc Surg 1975;16:241-60
  10. Galinanes M, Shattock MJ, Hearse DJ. Effects of potassium channel modulation during global ischaemia in isolated rat heart with and without cardioplegia. Cardiovasc Res 1992; 26:1063-8 https://doi.org/10.1093/cvr/26.11.1063
  11. Careaga G, Arguero R, Chavez-Negrete A, et al. Control of myocardial reperfusion injury with hypertonic-hyperosmotic solution in isolated rabbit heart. Eur Surg Res 1995;27: 269-76 https://doi.org/10.1159/000129409
  12. Fremes SE, Tamariz MG, Abramov D, et al. Late results of the Warm Heart Trial: the influence of nonfatal cardiac events on late survival. Circulation 2000;102(19 Suppl 3): 339-45
  13. Guru V, Omura J, Alghamdi AA, Weisel R, Fremes SE. Is blood superior to crystalloid cardioplegia? A meta- analysis of randomized clinical trials. Circulation 2006;114(Suppl 1): 331-8 https://doi.org/10.1161/CIRCULATIONAHA.106.624379
  14. Kron IL. Protection in the failing heart. Ann Thorac Surg 1999;68:1971-3 https://doi.org/10.1016/S0003-4975(99)01021-8
  15. Flack JE 3rd, Cook JR, May SJ, et al. Does cardioplegia type affect outcome and survival in patients with advanced left ventricular dysfunction? Results from the CABG Patch Trial. Circulation 2000;102(Suppl 3):III84-9
  16. Schlensak C, Doenst T, Kobba J, Beyersdorf F. Protection of acutely ischemic myocardium by controlled reperfusion. Ann Thorac Surg 1999;68:1967-70 https://doi.org/10.1016/S0003-4975(99)01022-X
  17. Jin XY, Gibson DG, Pepper JR. Early changes in regional and global left ventricular function after aortic valve replacement. Comparison of crystalloid, cold blood, and warm blood cardioplegias. Circulation 1995;92(Suppl II): 155-62 https://doi.org/10.1161/01.CIR.92.9.155
  18. Bouchart F, Bessou JP, Tabley A, et al. How to protect hypertrophied myocardium? A prospective clinical trial of three preservation techniques. Int J Artif Organs 1997;20: 440-6 https://doi.org/10.1177/039139889702000806
  19. Careaga G, Salazar D, Tellez S, Sanchez O, Borrayo G, Arguero R. Clinical impact of histidine-ketoglutaratetryptophan (HTK) cardioplegic solution on the perioperative period in open heart surgery patients. Arch Med Res 2001;32:296-9 https://doi.org/10.1016/S0188-4409(01)00296-X
  20. Kober IM, Obermayr RP, Brull T, Ehsani N, Schneider B, Spieckermann PG. Comparison of the solutions of Bretschneider, St. Thomas' Hospital and the National Institutes of Health for cardioplegic protection during moderate hypothermic arrest. Eur Surg Res 1998;30: 243-51 https://doi.org/10.1159/000008583
  21. Takeuchi K, Buenaventura P, Cao-Danh H, et al. Improved protection of the hypertrophied left ventricle by histidine containing cardioplegia. Circulation 1995;92(Suppl II):395-9
  22. Pulis RP, Wu BM, Kneteman NM, Churchill TA. Conservation of phosphorylation state of cardiac phosphofructokinase during in vitro hypothermic hypoxia. Am J Physiol Heart Circ Physiol 2000;279:H2151-8 https://doi.org/10.1152/ajpheart.2000.279.5.H2151
  23. Guarracino F, Landoni G, Tritapepe L, et al. Myocardial damage prevented by volatile anesthetics: a multicenter randomized controlled study. J Cardiothorac Vasc Anesth 2006;20:477-83 https://doi.org/10.1053/j.jvca.2006.05.012
  24. De Hert SG, Turani F, Mathur S, Stowe DF. Cardioprotection with volatile anesthetics: mechanisms and clinical implications. Anesth Analg 2005;100:1584-93 https://doi.org/10.1213/01.ANE.0000153483.61170.0C